8-K: BioCardia & CART-Tech Partner on Heart3D Imaging

BioCardia and CART-Tech have formed an exclusive partnership to develop and commercialize Heart3D Fusion Imaging for cardiac interventions.

Summary

• BioCardia, Inc. and CART-Tech, B.V. have entered into an exclusive development and commercialization agreement for Heart3D Fusion Imaging.
• The Heart3D system is designed to enhance two-dimensional x-ray images used in cardiac biotherapeutic delivery and biopsy procedures by fusing them with annotated pre-procedure three-dimensional anatomical heart models derived from MRI and CT images.
• The system is expected to be initially sold as a research tool with support services for partners in preclinical studies, with subsequent plans for approval for standard clinical practice.
• BioCardia will have exclusive worldwide distribution rights for biotherapeutic delivery and exclusive distribution rights for cardiac biopsy in the United States.
• All other distribution rights for Heart3D Fusion Imaging remain with CART-Tech.
• As part of the partnership, BioCardia has licensed global exclusive rights to CART-Tech's intellectual property for biotherapeutic intervention.
• CART-Tech has licensed global exclusive rights to BioCardia's intellectual property for cardiac resynchronization therapy.
• Management estimates that a single approved biologic therapy for a large market cardiology indication could potentially generate $100 million of annual revenue from Heart3D automated cloud-based image post-processing and live procedural guidance services if it becomes standard of care.
• Heart3D Fusion Imaging is currently for investigational use only and is not CE-marked or FDA approved.

Sentiment

Score: 8

Explanation: The announcement of an exclusive partnership for a potentially high-revenue product (estimated $100M annually if successful) in a growing field (biotherapeutics) is a strong positive. The cross-licensing of IP and leveraging of complementary expertise further enhances the positive outlook. The main caveat is the 'investigational use only' status and the forward-looking nature of the revenue estimate.

Positives

• Exclusive development and commercialization agreement for Heart3D Fusion Imaging, a novel technology aimed at enhancing cardiac interventions.
• Potential to significantly enhance the procedural experience for interventional cardiologists, improve therapeutic strategies for sponsors, and benefit patients.
• Management estimates a potential annual revenue of $100 million from Heart3D services if a single approved biologic therapy becomes standard of care in a large cardiology market.
• The partnership leverages both companies' clinical experience in positioning electrodes and drug delivery systems in the heart, along with their complementary intellectual property portfolios.
• BioCardia gains exclusive worldwide distribution rights for biotherapeutic delivery and exclusive U.S. rights for cardiac biopsy, expanding its market reach.
• Cross-licensing of intellectual property strengthens both companies' positions in their respective fields (biotherapeutic intervention for BioCardia, cardiac resynchronization therapy for CART-Tech).

Negatives

• Heart3D Fusion Imaging is currently for investigational use only and is not CE-marked or FDA approved, indicating significant regulatory hurdles and development work remain.
• The estimated $100 million annual revenue is a forward-looking statement contingent on a biologic therapy becoming standard of care, which introduces uncertainty.

Risks

• Forward-looking statements regarding investigational product candidates, fusion imaging capabilities, future development, potential markets, and future revenues are subject to many risks and uncertainties, and actual results may differ materially.
• The Heart3D system is currently for investigational use only and is not CE-marked or FDA approved, posing regulatory approval risks.
• Additional factors that could materially affect actual results can be found in BioCardia's Form 10-K filed on March 26, 2025, under 'Risk Factors,' and in subsequently filed Quarterly Reports on Form 10-Q.

Future Outlook

The Heart3D system is expected to enhance cardiac biotherapeutic delivery and biopsy procedures. It will initially be sold as a research tool with support services for preclinical studies and is subsequently expected to be approved for standard clinical practice. Management estimates a potential annual revenue of $100 million from Heart3D services if a single approved biologic therapy for a large cardiology market becomes standard of care.

Management Comments

• "Heart3D Fusion Imaging has potential to enhance the procedural experience for interventional cardiologists, improve therapeutic strategies for sponsors and most importantly, benefit patients." Peter Altman, BioCardia CEO.
• "This is a significant opportunity for both firms, as management estimates that a single approved biologic therapy for a large market cardiology indication could potentially generate $100 million of revenue annually from Heart3D automated cloud-based image post-processing and live procedural guidance services if it becomes standard of care." Peter Altman, BioCardia CEO.
• "The BioCardia team is looking forward to doing great things with the world class CART-Tech team. Together, we present the ultimate biotherapeutic delivery solution for partners developing cell, gene, and protein-based therapies to the heart." Peter Altman, BioCardia CEO.
• "The Heart3D Fusion Imaging product offering has potential to significantly enhance procedural planning and real time image precision for the delivery of biologic agent. Our mission is to help advance these therapies for the patients suffering from cardiovascular disease." Johan Maas, CART-Tech CEO.

Industry Context

This partnership represents a strategic move towards integrating advanced imaging technologies with biotherapeutic delivery in interventional cardiology. It addresses the growing need for precise guidance in complex cardiac procedures, particularly for novel cell, gene, and protein-based therapies. The focus on vendor-independent technology suggests a broader trend towards interoperability and enhanced precision in medical imaging within the cardiovascular field.

Stakeholder Impact

• Shareholders: Potential for a significant new revenue stream (estimated $100 million annually) if Heart3D becomes standard of care, enhancing long-term growth prospects.
• Patients: Potential for improved therapeutic strategies and enhanced procedural experience in cardiac biotherapeutic delivery and biopsy procedures.
• Interventional Cardiologists: Enhanced procedural experience and real-time image precision for complex cardiac interventions.
• Sponsors (of biologic therapies): Improved therapeutic strategies and a more precise delivery solution for cell, gene, and protein-based therapies to the heart.

Next Steps

• Advance Heart3D Fusion Imaging for biotherapeutic interventions and cardiac biopsy.
• Initially sell the Heart3D system as a research tool with support services for partners in preclinical studies.
• Seek regulatory approval (CE-mark or FDA) for the Heart3D system for standard clinical practice.

Key Dates

Recommendation

The exclusive partnership for Heart3D Fusion Imaging represents a significant strategic move for BioCardia, potentially opening a new, high-value revenue stream estimated at $100 million annually if the technology becomes standard of care for a large cardiology indication. This leverages BioCardia's existing expertise in biotherapeutic delivery and expands its product offering into critical imaging guidance. While the product is currently investigational and regulatory approvals are pending, the potential market impact and the complementary nature of the partnership with CART-Tech suggest a strong long-term growth opportunity. The cross-licensing of intellectual property further solidifies the strategic alignment and competitive positioning. This development significantly enhances the company's future prospects beyond its existing clinical-stage product candidates.

Keywords

BioCardia, BCDA, CART-Tech, Heart3D, Fusion Imaging, Cardiac Interventions, Biotherapeutic Delivery, Cardiac Biopsy, Medical Devices, Biotechnology, Cardiovascular Disease, Interventional Cardiology, Exclusive Agreement, Medical Imaging